Finally, Children of All Ages Can Benefit from 3HP to Prevent TB!
November 13, 2024 — The Community Research Advisors Group (CRAG) celebrates both the findings and the methodology of Study 35, a phase I/II clinical trial of the tuberculosis (TB) preventive treatment regimen known as 3HP in children.

TAG Statement on the Global Fund and Other Funding Sources to Fight TB, HIV, and Other Pandemics
November 11, 2024 — In advance of the 52nd Meeting of the Board of the Global Fund to Fight AIDS, Tuberculosis, and Malaria (the Global Fund) and the 2024 Union World Conference on Lung Health, Treatment Action Group (TAG) releases this statement in response to ongoing conversations about the Global Fund’s program allocations for…

Statement from TAG’s TB Project on Today’s WHO Global TB Report Release
October 29, 2024 — Treatment Action Group (TAG) is deeply concerned by the reported decrease in domestic funding for tuberculosis (TB) services announced today in the World Health Organization’s 2024 Global Tuberculosis Report.

Gilead Deal to Expand Access to Lenacapavir for PrEP Falls Short
October 8, 2024 — TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.

Statement on the UN High Level Meeting on Antimicrobial Resistance Final Draft Political Declaration
September 25, 2024 — Treatment Action Group (TAG) congratulates Malta and Barbados, co-facilitators, and all United Nations (UN) Member States participating in the High-Level Meeting on Antimicrobial Resistance (AMR) upon the publication of the final draft of the Political Declaration.

2024 Research in Action Awards Celebrate Leaders in Global Health Activism Who Exemplify TAG’s Mission
September 16, 2024 — Treatment Action Group’s (TAG) most important fundraising event of the year is the Research in Action Awards, which honor the best and brightest activists, researchers, leaders, and scientists whose work has been integral in ending HIV, tuberculosis (TB), and hepatitis C (HCV).

Treatment Action Group Calls for Coordinated, Fully Funded Global Response to Mpox Emergency
August 14, 2024 — Treatment Action Group (TAG) supports the World Health Organization (WHO) in declaring the renewed outbreak of mpox a public health emergency of international concern.

TAG Calls for Universal Access to Innovative HCV Testing to End the Disease by 2030
July 25, 2024 — This World Hepatitis Day, July 28, we are better positioned than ever to end hepatitis C Virus (HCV) as a pandemic.

Three New Members Elected to TAG’s Board of Directors
July 25, 2024 — Treatment Action Group (TAG) elected three new members to its Board of Directors in May 2024. Board President Ivy Kwan Arce said, “TAG is reinvigorating its Board in alignment with our vision, mission, and values.

TAG Calls on Danaher to Drop the Prices of GeneXpert Tests and Make the Cost Audit Public
June 26, 2024 — Treatment Action Group (TAG) calls on Danaher to lower the price of GeneXpert tests for tuberculosis (TB) and other diseases to $5 each in accordance with publicly available evidence of the cost of manufacturing and to commit to public transparency of the cost audit of Xpert MTB/RIF Ultra.